A5108591050- Coronary Interventions and Diagnostics
- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Cardiac Imaging and Diagnostics
- Cardiac Valve Diseases and Treatments
- Venous Thromboembolism Diagnosis and Management
- Cardiac pacing and defibrillation studies
- Cardiovascular Function and Risk Factors
- Heart Failure Treatment and Management
- Cerebrovascular and Carotid Artery Diseases
- Pulmonary Hypertension Research and Treatments
- Cardiovascular Issues in Pregnancy
- Peripheral Artery Disease Management
- COVID-19 Clinical Research Studies
- Cardiac Arrhythmias and Treatments
- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- Vascular Procedures and Complications
- Cardiac, Anesthesia and Surgical Outcomes
- Central Venous Catheters and Hemodialysis
- Pain Management and Treatment
- Cardiac Health and Mental Health
- Atherosclerosis and Cardiovascular Diseases
- Lipoproteins and Cardiovascular Health
- Atrial Fibrillation Management and Outcomes
Care Institute of Medical Sciences
2016-2025
Cleveland Clinic
2015-2020
B.J. Medical College
2007-2018
Pain Clinic of India
2018
University Hospitals Cleveland Medical Center
2015-2016
Life Care Institute of Medical Sciences & Research
2016
Shanghai Pulmonary Hospital
2013
University of Rochester Medical Center
2013
Tongji University
2013
Instituto Nacional de Cardiología
2013
Cangrelor, a nonthienopyridine adenosine triphosphate analogue, is an intravenous blocker of the diphosphate receptor P2Y12. This agent might have role in treatment patients who require rapid, predictable, and profound but reversible platelet inhibition.
Background— Reduced renal function is associated with a poorer prognosis and increased bleeding risk in patients acute coronary syndromes may therefore alter the risk-benefit ratio antiplatelet therapies. In Platelet Inhibition Patient Outcomes (PLATO) trial, ticagrelor compared clopidogrel reduced primary composite end point of cardiovascular death, myocardial infarction, stroke at 12 months but similar major rates. Methods Results— Central laboratory serum creatinine levels were available...
Background— Pulmonary arterial hypertension (PAH) is a progressive, fatal disease with no cure. Parenteral and inhaled prostacyclin analogue therapies are effective for the treatment of PAH, but complicated administration requirements can limit use these in patients less severe disease. This study was designed to evaluate safety efficacy oral treprostinil diolamine as initial de novo PAH. Methods Results— Three hundred forty-nine (intent-to-treat population) not receiving endothelin receptor...
Objective: The ORBIT I trial evaluated the safety and performance of an orbital atherectomy system (OAS) for treatment de novo calcified coronary lesions. Background: Severely arteries pose ongoing challenge. Stent placement in lesions can result stent under expansion, malapposition, procedural complications. OAS may change lesion compliance to reduce complications facilitate placement. Methods: trial, a prospective, nonrandomized study, was conducted two centers India. Fifty patients with...
Background Data comparing outcomes in heart failure ( HF ) across Asia are limited. We examined regional variation mortality among patients with enrolled the ASIAN ‐HF (Asian Sudden Cardiac Death Heart Failure) registry separate analyses for those reduced ejection fraction EF ; <40%) versus preserved (≥50%). Methods and Results The ‐ is a prospective longitudinal study. Participants symptomatic were recruited from 46 secondary care centers 3 Asian regions: South (India), Southeast...
Hemostatic devices are critical for managing emergent severe bleeding. With the increased use of anticoagulant therapy, there is a need next-generation hemostats. We rationalized that hemostat with an architecture designed to increase contact blood, and engineered from material activates distinct undrugged coagulation pathway can address emerging need. Inspired by lung alveolar architecture, here, we describe engineering single-phase chitosan tortuous spherical microporous design enables...
Long stents reduce the risk for in-stent restenosis associated with percutaneous coronary interventions in long, tapered lesions. The Morph India study investigated long-term safety and clinical performance of BioMime sirolimus-eluting stent (SES), a used treating long This is prospective, multicentre, single-arm, real-world, post-marketing surveillance conducted among patients lesions (length >26 mm to ≤56 mm, reference vessel diameter 2.25-3.50 mm) implanted SES. primary endpoint was...
Bicuspid aortic valve (BAV) is the most common valvular congenital anomaly and apparent in nearly 50% of candidates for AV replacement. While transcatheter implantation (TAVI) a recommended treatment patients with symptomatic severe stenosis (AS) at all surgical risk levels, experience TAVI bicuspid AS limited. BAV still challenge due to its association multiple complex anatomical considerations. A retrospective study has been conducted investigate TAVI's procedural 30-day outcomes using...
It is unclear whether primary aspiration can prevent distal embolisation and thereby improve myocardial perfusion in patients presenting with acute infarction (AMI) within 12 hours after onset.At 24 centres Europe India, 249 AMI were randomised to the Export catheter (Medtronic Vascular, Santa Rosa, CA, U.S.A.) followed by stenting (N=120) or conventional without (N=129). There no significant differences between 2 groups baseline characteristics target lesion TIMI scores. Procedure time was...
The ORBIT I trial evaluated the safety and performance of an orbital atherectomy system (OAS) in treating de novo calcified coronary lesions. Severely arteries pose ongoing treatment challenges. Stent placement lesions can result stent under expansion, malapposition procedural complications. OAS may be recommended to facilitate implantation these difficult lesions.Fifty patients with were enrolled trial. Patients treated followed by placement. Our institution 33/50 continued follow-up for 3...
The ORBIT I trial, a first-in-man study, was conducted to evaluate the safety and performance of orbital atherectomy system (OAS) in treating de novo calcified coronary lesions.Fifty patients were enrolled between May July 2008 based on several criteria, treated with OAS followed by stent placement. evaluated procedural success, device overall major adverse cardiovascular event (MACE) rates, including cardiac death, myocardial infarction (MI) need for target lesion revascularization (TLR)....
Background: Little is known regarding the impact of socioeconomic factors on use evidence-based therapies and outcomes in patients with heart failure reduced ejection fraction across Asia. Methods: We investigated association both patient-level (household income, education levels) country-level (regional income level by World Bank classification, disparity Gini index) indicators guideline-directed therapy clinical (composite 1-year mortality or HF hospitalization, quality life) prospective...
Background: Bicuspid aortic valve (BAV) affects approximately 1.5% of the general population and is seen in nearly 50% candidates for replacement (AVR). Despite increasingly utilised transcatheter implantation (TAVI) stenosis (AS) patients, its use among patients with severe bicuspid AS limited as BAV a heterogeneous disease associated multiple complex anatomical challenges. Aim: To investigate one-year outcomes TAVI using balloon-expandable Myval heart (THV) (Meril Life Sciences Pvt. Ltd.,...
No or slow reflow following percutaneous coronary intervention (PCI), despite the presence of a patent epicardial vessel, is serious complication resulting in increased morbidity and mortality. In present study, we have evaluated combination therapy adenosine sodium nitroprusside administered as sequential intracoronary (IC) boluses on no-reflow during PCI. Seventy-five high risk acute syndrome patients who underwent PCI with evidence initial less than TIMI (thrombolysis myocardial...
To present data from the cohort of patients in all-comers Endeavor zotarolimus-eluting stent (ZES) registry (E-Five) who underwent 2-year follow-up.The ZES has been shown to be safe and efficacious for treatment single, de novo lesions with stable coronary artery disease. E-Five evaluated over 8,000 real-world patients, at 188 sites followed 1 year. A subset continued follow-up through 2 years evaluate late-term safety effectiveness this population diverse clinical lesion...